Blueprint Medicines Corp Total Liabilities
Blueprint Medicines Corp total liabilities. Based on the latest financial reports, Blueprint Medicines Corp (BPMC) has total liabilities worth $853.47 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BPMC cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Blueprint Medicines Corp (2013–2024)
Total liabilities of Blueprint Medicines Corp from 2013 to 2024. This chart illustrates how Blueprint Medicines Corp's total liabilities have evolved over time, based on quarterly financial data. Check BPMC asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Blueprint Medicines Corp Competitors by Total Liabilities
The table below lists competitors of Blueprint Medicines Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NHPC Limited
NSE:NHPC
|
India | Rs645.23 Billion |
|
SPX Corp
NYSE:SPXC
|
USA | $1.59 Billion |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
USA | $1.04 Billion |
|
Norwegian Cruise Line Holdings Ltd
NYSE:NCLH
|
USA | $21.36 Billion |
|
Restaurant Brands International Limited Partnership
TO:QSP-UN
|
Canada | CA$19.59 Billion |
|
Quinenco
SN:QUINENCO
|
Chile | CL$52.97 Trillion |
|
Valmont Industries Inc
NYSE:VMI
|
USA | $1.73 Billion |
|
Oshkosh Corporation
NYSE:OSK
|
USA | $5.52 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Blueprint Medicines Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BPMC total asset value.
Liquidity & Leverage Metrics
Blueprint Medicines Corp Total Liabilities Ratios Explained
Blueprint Medicines Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Blueprint Medicines Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Blueprint Medicines Corp (2013–2024)
The table below shows the annual total liabilities of Blueprint Medicines Corp from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $881.15 Million | -4.08% |
| 2023-12-31 | $918.64 Million | +9.99% |
| 2022-12-31 | $835.23 Million | +196.72% |
| 2021-12-31 | $281.49 Million | +13.36% |
| 2020-12-31 | $248.31 Million | +2.04% |
| 2019-12-31 | $243.34 Million | +100.91% |
| 2018-12-31 | $121.11 Million | +31.98% |
| 2017-12-31 | $91.77 Million | +31.63% |
| 2016-12-31 | $69.72 Million | +99.65% |
| 2015-12-31 | $34.92 Million | +140.89% |
| 2014-12-31 | $14.50 Million | +157.43% |
| 2013-12-31 | $5.63 Million | -- |
About Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast … Read more